Zymeworks Inc. to acquire Theravance Biopharma, Inc.

Zymeworks Inc. has agreed to acquire Theravance Biopharma, Inc. in a strategic acquisition within the healthcare sector. The transaction, announced on 28 June 2026, involves consideration comprising both cash and an earn-out component. Zymeworks is a United States-based entity, while Theravance Biopharma is incorporated in the Cayman Islands. The deal structure reflects a standard strategic consolidation, with no specific headline offer value reported in the available data. The combination of immediate cash payment and contingent future payments suggests a structured approach to valuing the target’s ongoing performance and milestones.

The transaction was completed on 23 September 2026, marking the finalisation of the acquisition process. This timeline indicates a period of approximately three months between the initial announcement and the closing of the deal. The completion status confirms that all necessary conditions and approvals have been satisfied, allowing Zymeworks to fully integrate Theravance Biopharma into its corporate structure. The absence of a reported deal value prevents any quantitative assessment of the transaction size, but the structural elements of cash and earn-out remain the defining features of the agreement. The deal is now concluded.